On ECHEMI
Home > Drugs > Yunnan Biovalley Pharmaceutical Co., Ltd.
Yunnan Biovalley Pharmaceutical Co., Ltd.
  • Founded in:

    1999-06-13
  • Country:

    China China
  • Address:

    No. 1, Kangjian Road, Yunnan Mile Industrial Park, Fucheng Subdistrict Office, Mile City, Honghe Hani and Yi Autonomous Prefecture, Yunnan Province
  • Tax NO.:

    915301007134092367
  • Registered Funds:

    124.00007 million yuan
  • Website:

  • Email:

Related Drugs
Phellodendron chinense tablets
Palmitoyl hydrochloride.
Name Description Content CAS NO. Registered Holders
Palmitoyl Hydrochloride

1. Outstanding antibacterial effect: It has obvious antibacterial effect on Staphylococcus, Candida (fungus), Asian B virus, acid-fast bacilli and various Gram-positive and negative bacteria. 2. It has obvious inhibitory effect on Gram-positive and negative bacteria. 3. Enhance immune function: Strengthen the body's defense function (enhance the phagocytic ability of white blood cells). 4. It has obvious antibacterial effect on Helicobacter pylori.

More

1. Outstanding antibacterial effect: It has obvious antibacterial effect on Staphylococcus, Candida (fungus), Asian B virus, acid-fast bacilli and various Gram-positive and negative bacteria. 2. It has obvious inhibitory effect on Gram-positive and negative bacteria. 3. Enhance immune function: Strengthen the body's defense function (enhance the phagocytic ability of white blood cells). 4. It has obvious antibacterial effect on Helicobacter pylori.

0
Houttuynia cordata injection
Fresh Houttuynia cordata, auxiliary ingredients are sodium chloride and polysorbate-.
Name Description Content CAS NO. Registered Holders
Fresh Houttuynia cordata

Multiple tests conducted in accordance with the requirements of the "Standards for the Management of Non-clinical Drug Research" have shown that this product has no abnormal toxic reactions, no adverse effects of antihypertensive substances, no allergic reactions, and no obvious effects on animal activities, food intake, weight gain, etc.

More

Multiple tests conducted in accordance with the requirements of the "Standards for the Management of Non-clinical Drug Research" have shown that this product has no abnormal toxic reactions, no adverse effects of antihypertensive substances, no allergic reactions, and no obvious effects on animal activities, food intake, weight gain, etc.

0
Sodium chloride

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

More

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

7647-14-5 43
Tween 85

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

More

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

9005-70-3 0
Houttuynia cordata injection
Fresh Houttuynia cordata, auxiliary ingredients are sodium chloride and polysorbate-.
Name Description Content CAS NO. Registered Holders
Fresh Houttuynia cordata

In accordance with the requirements of the "Non-clinical Research Management Standards for Drugs" and relevant national guidelines for preclinical research of new drugs, tests were conducted on mice, guinea pigs and cats. The results showed no abnormal toxic reactions, met the requirements for antihypertensive substances, and there were no allergic reactions or deaths.

More

In accordance with the requirements of the "Non-clinical Research Management Standards for Drugs" and relevant national guidelines for preclinical research of new drugs, tests were conducted on mice, guinea pigs and cats. The results showed no abnormal toxic reactions, met the requirements for antihypertensive substances, and there were no allergic reactions or deaths.

0
Sodium chloride

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

More

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

7647-14-5 43
Tween 85

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

More

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

9005-70-3 0
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.